A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01221259
A Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01209858
- Locations
- ๐ฌ๐ง
Quintiles Ltd, London, United Kingdom
Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01177540
A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT01161524
A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT01153659
- Locations
- ๐บ๐ธ
Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States
An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT01146509
- Locations
- ๐บ๐ธ
Diamond Headache Clinical, Chicago, Illinois, United States
๐บ๐ธElkind Headache Center, Mount Vernon, New York, United States
๐บ๐ธThe Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01142661
A Study in Subjects With Recurrent Malignant Glioma
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT01137604
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 182
- Registration Number
- NCT01136967
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT01136733
ยฉ Copyright 2024. All Rights Reserved by MedPath